This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Anti-CD19 chimeric antigen receptor T cells made from umbilical cord blood cells had a distinct phenotype and may offer off-the-shelf potential.
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
Evidence is emerging about the safety and efficacy of CAR-T therapy and CRISPR-based editing techniques in cancer patients with HIV.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
A critical step in the preparation of autologous CAR-T therapy is the ex vivo proliferation of T cells from samples obtained from leukapheresis.
Community oncologists help refer appropriate patients to authorized treatment centers.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors.
A second-generation CD19 chimeric antigen receptor T cell therapy appeared to be effective in patients with B-cell acute lymphoblastic leukemia.
